Loading...
XSWX
NWRN
Market cap459mUSD
Dec 04, Last price  
18.52CHF
1D
3.58%
1Q
98.93%
Jan 2017
-8.09%
IPO
-64.99%
Name

Newron Pharmaceuticals SpA

Chart & Performance

D1W1MN
XSWX:NWRN chart
P/E
24.93
P/S
7.69
EPS
0.79
Div Yield, %
—
Shrs. gr., 5y
0.79%
Rev. gr., 5y
48.83%
Revenues
51m
+467.41%
01,191,0004,024,0003,933,0002,542,000806,000280,0008,924,0003,539,0001,557,0002,380,0006,726,00013,428,0004,025,0007,038,0005,258,0005,762,0006,094,0009,057,00051,390,000
Net income
16m
P
-14,919,000-16,401,000-11,089,000-16,364,000-23,481,000-20,545,000-6,445,000-2,375,000-7,098,000-10,095,000-22,816,000-15,237,000-5,282,000-15,035,000-20,207,000-20,998,000-14,901,000-17,493,000-16,224,00015,843,000
CFO
-18m
L+73.71%
-14,329,000-9,630,000-13,866,000-19,932,000-23,056,000-19,127,000-4,942,0005,825,000-10,686,000-9,998,000-12,862,000-19,583,000-8,404,000-15,954,000-21,976,000-15,588,000-11,445,000-11,092,000-10,140,000-17,614,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.
URL
https://www.newron.com/
IPO date
Dec 12, 2006
Employees
23
Domiciled in
IT
Incorporated in
IT

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT